0001415889-22-012966.txt : 20221223 0001415889-22-012966.hdr.sgml : 20221223 20221223162337 ACCESSION NUMBER: 0001415889-22-012966 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221221 FILED AS OF DATE: 20221223 DATE AS OF CHANGE: 20221223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ni Fang CENTRAL INDEX KEY: 0001895910 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39200 FILM NUMBER: 221485638 MAIL ADDRESS: STREET 1: C/O BLACK DIAMOND THERAPEUTICS, INC. STREET 2: ONE MAIN STREET, 10TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Black Diamond Therapeutics, Inc. CENTRAL INDEX KEY: 0001701541 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-417-5868 MAIL ADDRESS: STREET 1: ONE MAIN STREET, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Aset Therapeutics, Inc. DATE OF NAME CHANGE: 20170321 4 1 form4-12232022_091226.xml X0306 4 2022-12-21 0001701541 Black Diamond Therapeutics, Inc. BDTX 0001895910 Ni Fang C/O BLACK DIAMOND THERAPEUTICS, INC. ONE MAIN STREET, 14TH FLOOR CAMBRIDGE MA 02142 false true false false SEE REMARKS Common Stock 2022-12-21 4 P 0 20000 1.2885 A 89026 D Common Stock 2022-12-22 4 P 0 36363 1.2814 A 125389 D The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.27 to $1.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.23 to $1.3099, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Officer Title: Chief Business Officer and interim Chief Financial Officer Brent Hatzis-Schoch, as Attorney-in-Fact 2022-12-23